The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 685K Compounds and 4.6K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

41 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.EBI
Pfizer
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.EBI
Pfizer
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.EBI
Pfizer
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).EBI
Pfizer
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.EBI
Pfizer
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.EBI
Pfizer
The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.EBI
Pfizer
Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.EBI
Guangzhou University of Chinese Medicine
Identification of Novel Quinolin-2(1EBI
Sun Yat-Sen University
Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.EBI
Massachusetts General Hospital
The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.EBI
Rural Federal University of Rio De Janeiro
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.EBI
Sun Yat-Sen University
Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.EBI
Sun Yat-Sen University
Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.EBI
Hainan University
Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.EBI
China Pharmaceutical University
Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.EBI
Sun Yat-Sen University
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.EBI
Sun Yat-Sen University
Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.EBI
Sun Yat-Sen University
Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine.EBI
Smithkline Beecham Pharmaceuticals
Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines.EBI
Celon Pharma
Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1.EBI
Pfizer
Spirocyclic compoundsBDB
C4 Therapeutics
Compositions and methods for treating CNS disordersBDB
Sage Therapeutics
Substituted piperidine compounds and their useBDB
Eisai R&D Management
Substituted macrocyclic indole derivativesBDB
Bayer Aktiengesellschaft
Piperazine derivatives as MAGL inhibitorsBDB
Hoffmann-La Roche
Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitorsBDB
Shenzhen Targetrx
Substituted pyridines as TYK2 inhibitorsBDB
Esker Therapeutics
Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2BDB
Effector Therapeutics
Piperidines as menin inhibitorsBDB
The Regents of The University of Michigan
Inhibitors of cyclin-dependent kinasesBDB
Kinnate Biopharma
Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitorsBDB
Vanderbilt University
Inhibitors of TRPC6BDB
Boehringer Ingelheim International
HIV protease inhibitorsBDB
Gilead Sciences
Pyrrolopyrimidine comprising cyclopentyl substituentBDB
Centaurus Biopharma
Tricyclic compounds as inhibitors of mutant IDH enzymesBDB
Merck Sharp & Dohme
Oxime-based compound, pharmaceutical composition containing the same and method for preparing the sameBDB
Chang Gung University
Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus.BDB
Paris-Sud University
Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase.BDB
Northwestern University